Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

3.67USD
18 May 2018
Change (% chg)

$0.01 (+0.27%)
Prev Close
$3.66
Open
$3.68
Day's High
$3.74
Day's Low
$3.64
Volume
95,186
Avg. Vol
297,283
52-wk High
$8.75
52-wk Low
$2.06

Chart for

About

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $188.97
Shares Outstanding(Mil.): 51.63
Dividend: --
Yield (%): --

Financials

  TTPH.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -2.34 -- --
ROI: -92.41 13.08 12.63
ROE: -92.52 14.80 14.50

BRIEF-Tetraphase Pharma Q4 Loss Per Share $0.46

* TETRAPHASE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS, HIGHLIGHTS ACHIEVEMENTS AND KEY 2018 MILESTONES

Mar 06 2018

BRIEF-Tetraphase Pharmaceuticals Says FDA Accepted NDA Filing For cIAI Treatment Eravacycline

* TETRAPHASE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR FILING OF ITS NDA SUBMISSION FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

Feb 27 2018

BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines

* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA

Feb 20 2018

Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

Feb 13 2018

Tetraphase's antibiotic fails late-stage study, shares plummet

Feb 13 Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

Feb 13 2018

BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI

* TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI)

Feb 13 2018

BRIEF-Tetraphase Pharmaceuticals Files For Mixed Shelf Of Up To $150 Mln

* FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2n8xDCf) Further company coverage:

Jan 25 2018

BRIEF-Tetraphase Pharmaceuticals Announces Submission Of NDA To FDA For Eravacycline To Treat Intra-Abdominal Infections

* TETRAPHASE PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

Jan 02 2018

BRIEF-Millennium Management Llc Reports 5.3 Pct Passive Stake In Tetraphase Pharmaceuticals As On Dec 14

* MILLENNIUM MANAGEMENT LLC REPORTS 5.3 PERCENT PASSIVE STAKE IN TETRAPHASE PHARMACEUTICALS AS ON DEC 14 - SEC FILING Source text: (http://bit.ly/2kt52WQ) Further company coverage:

Dec 20 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.24 +0.39
Pfizer Inc. (PFE.N) $35.64 -0.07
Merck & Co., Inc. (MRK.N) $59.14 +0.07
AstraZeneca plc (AZN.L) 5,241.00 -104.00

Earnings vs. Estimates